Why is Biohaven (NYSE:BHVN) presenting BHV-1530 data?

Biohaven (NYSE:BHVN) is presenting BHV-1530 data to provide updated Phase 1 results from its ongoing BHV1530-101 clinical study at the EORTC-NCI-AACR oncology symposium.

What is BHV-1530 from Biohaven (NYSE:BHVN)?

BHV-1530 from Biohaven (NYSE:BHVN) is an FGFR3-directed antibody-drug conjugate being evaluated in adults with advanced or metastatic solid tumors.

Is Biohaven (NYSE:BHVN) testing BHV-1530 with other treatments?

Biohaven (NYSE:BHVN) has begun enrolling a cohort testing BHV-1530 with cemiplimab under a clinical supply agreement with Regeneron Pharmaceuticals.

What does the BHV-1530 study evaluate?

The BHV-1530 study from Biohaven (NYSE:BHVN) evaluates the treatment alone and in combination with cemiplimab through dose escalation, expansion, and confirmation phases in adults with advanced solid tumors.

Health

Image for illustrative purposes only. Not a real photo.

Biohaven to present BHV-1530 cancer data

Q: What results has Biohaven (NYSE:BHVN) previously reported for BHV-1530?

Biohaven (NYSE:BHVN) previously reported confirmed partial responses in heavily pretreated patients, with no dose-limiting toxicities or FGFR inhibitor-class toxicities observed in reported data.

Escrito por Liezl GambePublished Sep 28, 2026, 12:00 PM

Biohaven will present updated Phase 1 clinical data for BHV-1530 at the EORTC-NCI-AACR oncology symposium in November 2026.
The study is evaluating an FGFR3-directed antibody-drug conjugate in adults with advanced or metastatic solid tumors.
Biohaven has started a combination cohort testing BHV-1530 with cemiplimab under a clinical supply agreement with Regeneron.

Biohaven (NYSE:BHVN) will present updated Phase 1 data for BHV-1530 at the EORTC-NCI-AACR oncology symposium in November 2026, covering the ongoing BHV1530-101 study.

The November 19 oral presentation in Barcelona will provide additional results from the trial evaluating BHV-1530, an FGFR3-directed antibody-drug conjugate, in adults with advanced or metastatic solid tumors.

Biohaven said previously disclosed data included confirmed partial responses in heavily pretreated patients, with no dose-limiting toxicities or FGFR inhibitor-class toxicities observed in the reported results.

Biohaven develops therapies across neurological, immunological, and oncology-related disease areas, including antibody-based drug candidates.

The company said it has started enrolling patients in a cohort evaluating BHV-1530 in combination with cemiplimab, with the study including dose escalation, expansion, and confirmation stages.

Perguntas frequentes

2 months ago

Biohaven and Yale secure $4 million verdict in trade secret and contract dispute

Biohaven (NYSE:BHVN) and Yale University announced a favorable verdict from a federal jury in the U.S. District Court for the District of Delaware regarding their ongoing litigation against Avilar Therapeutics and RA Capital.

Leia mais

4 months ago

Biohaven autoimmune degraders clear key biomaker milestones as Phase 3 nears

Biohaven (NYSE:BHVN) reported positive preliminary clinical data from its ongoing Phase 1b trials evaluating two novel extracellular protein degraders, hitting key biological markers and clearing a path toward advanced clinical development.

Leia mais

4 months ago

Biohaven seizure drug extends remission in broad clinical data update

Biohaven (NYSE:BHVN) released new clinical and safety data for opakalim, its selective Kv7.2/7.3 potassium channel activator, showing meaningful reductions in seizure frequency and a highly differentiated central nervous system safety profile across generalized and focal forms of epilepsy.

Leia mais